Evidence map›Paper›PMID 37744271›Full record

ArticleOncology research2023

Deciphering key genes involved in cisplatin resistance in kidney renal clear cell carcinoma through a combined

Muneeba Malik, Mamoona Maqbool, Tooba Nisar, Tazeem Akhter, Javed Ahmed Ujan, Alanood S Algarni, Fakhria A Al Joufi, Sultan Shafi K Alanazi, Mohammad Hadi Almotared, Mounir M Salem Bekhit and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Muneeba MalikServices Hospital, Lahore, Pakistan.
Mamoona MaqboolSabzazar Medical Center, Lahore, Pakistan.
Tooba NisarBHU Pourmiana, Attock, Pakistan.
Tazeem AkhterPublic Health Department, University of Health Sciences, Lahore, Pakistan.
Javed Ahmed UjanDepartment of Zoology, Shah Abdul Latif University, Khairpur, Pakistan.
Alanood S AlgarniPharmacology and Toxicology Department College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Fakhria A Al JoufiDepartment of Pharmacology, College of Pharmacy, Jouf University, Aljouf, Saudi Arabia.
Sultan Shafi K AlanaziRegional Laboratory and Blood Bank (Total Laboratory Automation), Riyadh, Saudi Arabia.
Mohammad Hadi AlmotaredHealth Affairs in Najran, New Najran General Hospital, Najran, Saudi Arabia.
Mounir M Salem BekhitDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Muhammad JamilPARC Arid Zone Research Center, Dera Ismail Khan, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The low survival rate of Kidney renal clear cell carcinoma (KIRC) patients is largely attributed to cisplatin resistance. Rather than focusing solely on individual proteins, exploring protein-protein interactions could offer greater insight into drug resistance. To this end, a series of

Indexed as

Carcinoma, Renal CellKidney NeoplasmsCisplatinHumansKidneySulfitesCisplatinhydrogen sulfiteSulfitesChemotherapyCisplatin resistanceKIRCOverall survival

Identifiers

PMID37744271
PMCPMC10513959

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.